摘要
目的分析伊马替尼联合VP低剂量方案初治成人Ph阳性急性淋巴细胞白血病的作用。方法选取2010年6月至2013年6月成人Ph阳性急性淋巴细胞白血病患者34例，随机分为观察组与对照组两组，每组17例，对照组患者给予VP低剂量方案治疗，观察组给予伊马替尼联合VP低剂量方案治疗，比较两组患者的血液学完全缓解率、复发率、不良反应发生率。结果观察组患者的血液学完全缓解率为88．24％，显著高于对照组（52．94％，P〈0．05）；观察组复发率为17．65％，显著低于对照组（52．94％，P〈0．05）；观察组总不良反应发生率为11．76％，显著低于对照组（52．94％，P〈0．05）。结论伊马替尼联合VP低剂量方案初治成人Ph阳性急性淋巴细胞白血病患者血液学缓解率显著提高，复发率降低，不良反应发生率低，能提高患者生存质量，值得临床推广应用。
Objective To analyze the effect of imatinib combined with VP low dose regimen on adult Ph chromosome positive acute lymphoblastic leukemia. Methods From June 2010 to June 2013, a total of 34 patients who accepted treatments were taken as the clinical research objects, and these pa- tients were randomly divided into observation group （17 cases） and control group （17 cases）. Patients in the control group were given VP low dose regimen, and the other patients in the observation group were given imatinib combined with VP low dose regimen. After treatment, the complete hematological remis- sion rate, recurrence rate and adverse reaction rate was compared. Results The complete hematological remission rate of the observation group was 88.24%, which was significantly higher than that of the con- trol group （52.94% ,P 〈0. 05） ; the recurrence rate of the observation group was 17.65%, which was significantly lower than that of the control group （ 52.94%, P 〈 0. 05 ） ; the adverse reaction rate of the observation group was 11.76%, which was significantly lower than that of the control group （52.94%, P 〈 0. 05 ）. Conclusions Imatinib combined with VP low dose regimen in the treatment of adult Ph chromosome positive acute lymphoblastic leukemia, has higher complete hematological remission rate, lower recurrence rate and adverse reaction rate, and can improve the survial rate of patients. So it is wor- thy of clinical application and promotion.
出处
《中国实用医刊》
2016年第23期24-26,共3页
Chinese Journal of Practical Medicine
